1. Academic Validation
  2. Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor

  • ACS Med Chem Lett. 2010 Mar 22;1(3):120-4. doi: 10.1021/ml1000239.
Kevin W Gillman 1 John E Starrett Jr 1 Michael F Parker 1 Kai Xie 1 Joanne J Bronson 1 Lawrence R Marcin 1 Kate E McElhone 1 Carl P Bergstrom 1 Robert A Mate 1 Richard Williams 2 Jere E Meredith Jr 3 Catherine R Burton 3 Donna M Barten 3 Jeremy H Toyn 3 Susan B Roberts 3 Kimberley A Lentz 4 John G Houston 3 Robert Zaczek 3 Charles F Albright 3 Carl P Decicco 1 John E Macor 1 Richard E Olson 1
Affiliations

Affiliations

  • 1 Neuroscience Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492.
  • 2 Medicinal Chemistry Department, Albany Molecular Research Incorporated, 26 Corporate Circle, Albany, New York 15098.
  • 3 Neuroscience Discovery Biology, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492.
  • 4 Metabolism and Pharmacokinetics, Bristol-Myers Squibb, 5 Research Parkway, Wallingford, Connecticut 06492.
Abstract

During the course of our research efforts to develop a potent and selective γ-secretase Inhibitor for the treatment of Alzheimer's disease, we investigated a series of carboxamide-substituted sulfonamides. Optimization based on potency, Notch/Amyloid-β precursor protein selectivity, and brain efficacy after oral dosing led to the discovery of 4 (BMS-708163). Compound 4 is a potent inhibitor of γ-secretase (Aβ40 IC50 = 0.30 nM), demonstrating a 193-fold selectivity against Notch. Oral administration of 4 significantly reduced Aβ40 levels for sustained periods in brain, plasma, and cerebrospinal fluid in rats and dogs.

Keywords

Alzheimer's; amyloid; brain penetrant; clinical candidate; oxadiazole; γ-Secretase.

Figures
Products